September 20, 2020

The Niche

Knoepfler lab stem cell blog

Friedreich’s Ataxia Research Alliance

1 min read

The REGROW Act would drastically weaken FDA regulation of experimental stem cell therapies. I’ve criticized it in numerous posts (see those here) for its radical ideas that would put patients and the stem cell field at risk. I’m not the only one concerned about it as both ARM and ISSCR oppose it too. Now 10 top patient advocacy groups together announced their opposition to it as well.  The patient groups that include the Michael J. Fox Foundation (see complete list at the bottom of this email) cited …Read More